B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Biological Psychiatry

• Publication date

  1993-05-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/0006-3223(93)90117-VPMID 8102551
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid and simple determination of homovanillic acid in plasma using high performance liquid chromatography with electrochemical detection.

  2009cited by this paper
• B-HT 920 is a full agonist at both pre- and postsynaptic D-2 dopamine receptors

  2005cited by this paper
• Partial improvement in negative schizophrenic symptoms after amphetamine

  2004cited by this paper
• Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

  2004cited by this paper
• B-HT 920 and B-HT 958: Presynaptic effects on electrically evoked 3H-dopamine release from slices of rat nucleus accumbens

  2004cited by this paper
• Dopamine in schizophrenia: a review and reconceptualization.

  1991cited by this paper
• B-HT920 - A Novel Dopamine Autoreceptor Agonist in the Treatment of Patients with Schizophrenia

  1990cited by this paper
• B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia.

  1990cited by this paper
• Neural Mechanisms of Negative Symptoms

  1989cited by this paper
• Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation.

  1988cited by this paper
• A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.

  1988cited by this paper
• Biological studies in schizophrenia.

  1987cited by this paper
• Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia.

  1987cited by this paper
• Implications of normal brain development for the pathogenesis of schizophrenia.

  1987cited by this paper
• Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.

  1986cited by this paper
• Clinical Effects of Apomorphine in Schizophrenia

  1984cited by this paper
• Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat.

  1984cited by this paper
• CNS Dopamine Autoreceptors: Distribution, Pharmacology, and Function a

  1984cited by this paper
• Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.

  1983cited by this paper
• Pharmacology of mesocortical dopamine neurons.

  1983cited by this paper
• d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

  1982cited by this paper
• Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively

  1982cited by this paper
• Negative symptoms in schizophrenia

  1982cited by this paper
• Dopamine autoreceptor stimulation: clinical significance.

  1982cited by this paper
• 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity.

  1979cited by this paper
• Catecholaminergic drugs in chronic schizophrenia.

  1979cited by this paper
• Schizophrenic symptoms improve with apomorphine.

  1978cited by this paper
• Clinical effect of L-dopa on schizophrenia.

  1976cited by this paper
• Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

  1976cited by this paper
• The effect of l-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs

  1975cited by this paper
• The effect of L-dopa on young patients with simple schizophrenia reated with neuroleptic subjects.

  1975cited by this paper
• Effect of L‐Dopa in Schizophrenia

  1972cited by this paper

• The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis

  2021cites this paper
• The role of dopamine in the pathophysiology and treatment of apathy.

  2016cites this paper
• Motivational Deficits in Schizophrenia

  2016cites this paper
• Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism

  2015cites this paper
• Neural substrates underlying effort computation in schizophrenia.

  2013cites this paper
• Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

  2010cites this paper
• Dopamine Receptors and the Treatment of Schizophrenia

  2010cites this paper
• Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1A receptors

  2007cites this paper
• Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.

  2006cites this paper
• Pergolide as Adjuvant Therapy to Amisulpride in the Treatment of Negative and Depressive Symptoms in Schizophrenia

  2006cites this paper
• Differential dopaminergic modulation of executive control in healthy subjects

  2005cites this paper
• Partial agonism and schizophrenia

  2005cites this paper
• WHY IS A PARTIAL AGONIST OF THEORETICAL INTEREST INSCHIZOPHRENIA?

  2004cites this paper
• Repeated Quinpirole Treatment Increases cAMP-Dependent Protein Kinase Activity and CREB Phosphorylation in Nucleus Accumbens and Reverses Quinpirole-Induced Sensorimotor Gating Deficits in Rats

  2004cites this paper
• Relationship Between Psychopathology and Regional Cerebral Blood Flow Detected by Tc-99m HMPAO SPECT in Patients with Predominantly Positive or Negative Schizophrenic Symptoms

  2001cites this paper
• Aboulia: neurobehavioural dysfunction of dopaminergic system?

  2000cites this paper
• Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs.

  1999cites this paper
• Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra

  1999cites this paper
• Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.

  1998cites this paper
• Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia.

  1998cites this paper
• Effects of Clozapine on Plasma Catecholamines and Relation to Treatment Response in Schizophrenia: A Within-Subject Comparison with Haloperidol

  1997cites this paper
• Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area.

  1996cites this paper
• Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy.

  1996cites this paper
• The management of treatment-resistant schizophrenia

  1995cites this paper
• Dopamine agonists in schizophrenia: a review.

  1995cites this paper
• Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain.

  1994cites this paper